March 25, 2022 11:16 AM EDTUpdated 02:56 PM

Big Pharma has skirted long Covid, but a pipeline of small biotechs is testing treatments for lingering symptoms

Kyle LaHucik

Senior Reporter

Long Covid has been partly mysterious, due to the nascency of SARS-CoV-2 as well as the vastness of lingering symptoms experienced by millions of people …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Big Pharma has skirted long Covid, but a pipeline of small biotechs is testing treatments for lingering symptoms

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Exclusive: Florida cancer biotech raises $100M Series A

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Big Phar­ma has skirt­ed long Covid, but a pipeline of small biotechs is test­ing treat­ments for lin­ger­ing symp­toms

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Big Pharma has skirted long Covid, but a pipeline of small biotechs is testing treatments for lingering symptoms

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Exclusive: Florida cancer biotech raises $100M Series A

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.